Auson Pharmaceuticals Inc

General

Total Cases3
Active Cases1
Patents4
CourtsD. DelawareD. New Jersey
TypeOperating Company
Elite Ratings
--
--
--
--

Ratings

Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered
Case
Description
10/25/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,539,218 B2; US 10,828,310 B2. (nms) (Entered: 10/25/2024)
10/25/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
SO ORDERED Granting [76] Stipulation of Dismissal (***Civil Case Terminated). Signed by Judge Richard G. Andrews on 10/25/2024. (nms) (Entered: 10/25/2024)
10/24/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
STIPULATION of Dismissal by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals Inc.. (Fahnestock, Derek) (Entered: 10/24/2024)
10/22/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
REDACTED VERSION of [73] Stipulation, filed by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals Inc.. (Fahnestock, Derek) Modified on 10/22/2024 (nms). (Entered: 10/22/2024)
10/16/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
[SEALED] ORDER Granting Stipulation and Proposed Order to Stay (*Set Deadlines: Status Report due by 11/15/2024). Signed by Judge Richard G. Andrews on 10/16/2024.This order has been emailed to local counsel. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01103-RGA(nms) (Entered: 10/16/2024)
10/15/24
Bayer Intellectual Property GmbH v. Auson Pharmaceuticals Inc
1:23-CV-01103
 (
D. DE
)
[SEALED] STIPULATION and [Proposed] Order to Stay - by Bayer AG, Bayer Intellectual Property GMBH, Bayer Pharma AG, Janssen Pharmaceuticals Inc.. (Fahnestock, Derek) (Entered: 10/15/2024)
10/08/24
In re: Xarelto (Rivaroxaban) ('310) Patent Litigation
1:21-MD-03017
 (
D. DE
)
STIPULATION to Extend Time - filed by Hetero Labs Limited. (Dorsney, Kenneth) Modified on 10/8/2024 (nms). (Entered: 10/08/2024)
10/08/24
In re: Xarelto (Rivaroxaban) ('310) Patent Litigation
1:21-MD-03017
 (
D. DE
)
SO ORDERED, re [316] STIPULATION to Extend Time (*Reset Answer Deadlines: Hetero Labs Limited answer due 10/23/2024). Signed by Judge Richard G. Andrews on 10/8/2024. (nms) (Entered: 10/08/2024)
10/04/24
In re: Xarelto (Rivaroxaban) ('310) Patent Litigation
1:21-MD-03017
 (
D. DE
)
NOTICE of Voluntary Dismissal by Taro Pharmaceutical Industries Ltd., Taro Pharmaceuticals U.S.A., Inc. as to U.S. Patent 9,415,053 Counterclaims (Vrana, Robert) (Entered: 10/04/2024)
09/27/24
In re: Xarelto (Rivaroxaban) ('310) Patent Litigation
1:21-MD-03017
 (
D. DE
)
STIPULATION and Proposed Order to Extend Time - filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 9/27/2024 (nms). (Entered: 09/27/2024)